[go: up one dir, main page]

BR0212775A - Composto de 1,2,4-triazol - Google Patents

Composto de 1,2,4-triazol

Info

Publication number
BR0212775A
BR0212775A BR0212775-0A BR0212775A BR0212775A BR 0212775 A BR0212775 A BR 0212775A BR 0212775 A BR0212775 A BR 0212775A BR 0212775 A BR0212775 A BR 0212775A
Authority
BR
Brazil
Prior art keywords
group
compound
hyperuricemia
therapeutic agent
pyridyl
Prior art date
Application number
BR0212775-0A
Other languages
English (en)
Other versions
BRPI0212775B1 (pt
BRPI0212775B8 (pt
Inventor
Hiroshi Nakamura
Soichi Kaneda
Takahiro Sato
Naoki Ashizawa
Koji Matsumoto
Takashi Iwanaga
Tsutomu Inoue
Original Assignee
Fuji Yakuhin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Yakuhin Co Ltd filed Critical Fuji Yakuhin Co Ltd
Publication of BR0212775A publication Critical patent/BR0212775A/pt
Publication of BRPI0212775B1 publication Critical patent/BRPI0212775B1/pt
Publication of BRPI0212775B8 publication Critical patent/BRPI0212775B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE 1,2,4-TRIAZOL". é provido um novo composto de 1,2,4-triazol que é útil como um agente terapêutico para hiperuricemia e gota devido a hiperuricemia. Um composto é representado pela seguinte fórmula geral (1): [Substância química 6] em que R~ 2~ representa um grupo piridila não-substituído ou substituído, R~ 1~, representa um grupo piridila similar, um grupo piridina-N-óxido correspondente a estes grupos piridila, ou um grupo fenila, e R~ 3~ representa hidrogênio ou um grupo alquila inferior substituído por grupo pivaloilóxi e R~ 3~ se liga a um átomo de nitrogênio no anel. Também são promovidos um processo para a produção de um composto por reação de uma nitrila e uma hidrazida, e um agente terapêutico, particularmente um inibidor de oxidase de xantina.
BRPI0212775A 2002-01-28 2002-12-03 composto de 1,2,4-triazol e medicamento BRPI0212775B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002017825 2002-01-28
PCT/JP2002/012662 WO2003064410A1 (fr) 2002-01-28 2002-12-03 Nouveau compose 1,2,4-triazole

Publications (3)

Publication Number Publication Date
BR0212775A true BR0212775A (pt) 2004-10-13
BRPI0212775B1 BRPI0212775B1 (pt) 2017-06-06
BRPI0212775B8 BRPI0212775B8 (pt) 2021-05-25

Family

ID=27653386

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212775A BRPI0212775B8 (pt) 2002-01-28 2002-12-03 composto de 1,2,4-triazol e medicamento

Country Status (22)

Country Link
US (1) US7074816B2 (pt)
EP (1) EP1471065B1 (pt)
JP (1) JP3600832B2 (pt)
CN (1) CN1561340B (pt)
AR (1) AR042602A1 (pt)
AT (1) ATE387438T1 (pt)
AU (1) AU2002349754B2 (pt)
BR (1) BRPI0212775B8 (pt)
CA (1) CA2462132C (pt)
DE (1) DE60225341T2 (pt)
DK (1) DK1471065T3 (pt)
ES (1) ES2300486T3 (pt)
HK (1) HK1067132A1 (pt)
MX (1) MXPA04004037A (pt)
NO (1) NO326941B1 (pt)
NZ (1) NZ531673A (pt)
PL (1) PL208260B1 (pt)
PT (1) PT1471065E (pt)
RU (1) RU2293733C2 (pt)
TW (1) TWI257926B (pt)
WO (1) WO2003064410A1 (pt)
ZA (1) ZA200401777B (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009991A1 (ja) * 2003-07-24 2005-02-03 Fujiyakuhin Co., Ltd. １，２，４−トリアゾール化合物の製造方法及びその中間体
US20060189811A1 (en) * 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
EP1883405A4 (en) 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
CA2617248C (en) * 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
WO2007043400A1 (ja) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素芳香族複素環化合物およびそれを含有する医薬組成物
EP2036561B1 (en) * 2006-06-22 2017-05-10 Nippon Chemiphar Co., Ltd. Agent for overcoming resistance to anti-cancer agent
EP2050467B1 (en) * 2006-07-19 2014-09-10 Nippon Medical School Foundation Therapeutic agent for amyotrophic lateral sclerosis
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
KR20090103879A (ko) * 2006-11-13 2009-10-01 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
RU2009131454A (ru) * 2007-01-19 2011-02-27 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы предупреждения или уменьшения числа обострений подагры с применением ингибиторов ксантиноксидоредуктазы и противовоспалительных средств
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
RS53569B1 (en) 2007-11-27 2015-02-27 Ardea Biosciences, Inc. NEW COMPOUNDS AND COMPOSITIONS, AND PROCEDURES FOR USE
EP2165705A1 (en) 2008-09-18 2010-03-24 Centre National de la Recherche Scientifique (CNRS) Use of a compound capable of reducing the uric acid level for the prevention and/or the treatment of lung inflammation and fibrosis
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CN103298466B (zh) 2010-09-10 2015-11-25 武田制药美国有限公司 茶碱和非布索坦的联合治疗方法
WO2012060308A1 (ja) * 2010-11-01 2012-05-10 株式会社 三和化学研究所 腎機能障害の予防又は治療に用いる医薬
WO2012081736A1 (en) 2010-12-17 2012-06-21 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
US8541094B2 (en) 2011-03-01 2013-09-24 Empire Technology Development Llc Temperature controlled variable reflectivity coatings
RU2476428C1 (ru) * 2011-09-01 2013-02-27 Государственное образовательное учреждение высшего профессионального образования "Южно-Российский государственный технический университет (Новочеркасский политехнический институт)" Способ получения дигидрохлорида 5-амино-3-аминометил-1,2,4-триазола
ES2690315T3 (es) 2012-06-15 2018-11-20 Mitsubishi Tanabe Pharma Corporation Compuestos de imidazol y triazol como inhibidores de DGAT-1
WO2014017515A1 (ja) * 2012-07-25 2014-01-30 株式会社富士薬品 ４－［５－（ピリジン－４－イル）－１ｈ－１，２，４－トリアゾール－３－イル］ピリジン－２－カルボニトリルの結晶多形およびその製造方法
RU2644766C2 (ru) * 2012-07-25 2018-02-14 Фудзиякухин Ко., Лтд. Способ получения 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]пиридин-2-карбонитрила и его промежуточное соединение
CN103724329B (zh) * 2013-12-23 2015-02-18 济南百诺医药科技开发有限公司 4-[5-(吡啶-4-基)-1h-[1,2,4]三唑-3-基]吡啶-2-甲腈的制备方法
CN104042577B (zh) * 2014-06-13 2016-08-24 安徽省逸欣铭医药科技有限公司 一种稳定的托匹司他片及其制备方法
CN105315260A (zh) * 2014-07-29 2016-02-10 北京海步医药科技股份有限公司 一种托布司他一水合物晶型及其制备方法
CN105367490B (zh) * 2014-08-18 2019-01-04 上海医药工业研究院 合成托吡司他的新中间体及其制备方法
CN105348264B (zh) * 2014-08-18 2018-01-16 上海医药工业研究院 一种托吡司他的合成方法
CN104151297B (zh) * 2014-08-27 2016-03-16 王庆本 4-[5-(吡啶-4-基)-1h-[1，2，4]三唑-3-基]吡啶-2-甲腈的制备方法
JP6684264B2 (ja) * 2015-02-17 2020-04-22 株式会社三和化学研究所 心不全の予防又は治療のための医薬
CN107427517B (zh) 2015-02-24 2021-11-16 国立大学法人鸟取大学 用于痴呆症的预防及/或治疗的医药
WO2016134854A1 (en) 2015-02-25 2016-09-01 Pharmathen S.A. Methods for the preparation of topiroxostat and intermediates thereof
CN105693699B (zh) * 2015-03-30 2019-06-18 苏州晶云药物科技股份有限公司 托吡司他的晶型及其制备方法
CN104910068B (zh) * 2015-04-24 2017-07-14 南京医科大学 一种2‑氰基异烟酸酰肼1.5对甲苯磺酸盐的合成方法
CN106279111A (zh) * 2015-05-12 2017-01-04 北京济美堂医药研究有限公司 一种精制托吡司他的新方法
CN104961730B (zh) * 2015-06-18 2017-05-17 山东金城医药化工股份有限公司 托吡司他新晶型及其制备方法
CN105130958B (zh) * 2015-08-31 2017-10-31 济南康和医药科技有限公司 5‑(2‑氰基4‑吡啶基)‑3‑(4‑吡啶基)‑1,2,4‑三唑的制备工艺
CN105294656A (zh) * 2015-10-10 2016-02-03 大道隆达（北京）医药科技发展有限公司 一种托匹司他的制备工艺和方法
CN106336399A (zh) * 2015-11-03 2017-01-18 江苏悦兴药业有限公司 托匹司他工艺杂质的制备方法
CN105294584A (zh) * 2015-11-30 2016-02-03 中国医科大学 1-取代苯基-1h-1,2,3-三唑类化合物、制备方法及其用途
CN105399732A (zh) * 2015-12-07 2016-03-16 青岛正大海尔制药有限公司 一种托匹司他的制备方法
CN106008465A (zh) * 2016-03-16 2016-10-12 江苏悦兴药业有限公司 一种托匹司他杂质的合成方法
CN108250183A (zh) * 2016-12-29 2018-07-06 北京诚济制药有限公司 一种高纯度的托匹司他的制备方法
CN109721586B (zh) * 2017-10-27 2021-03-02 中国医科大学 一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN107652271B (zh) * 2017-11-06 2020-06-16 上海中拓医药科技有限公司 一种托匹司他晶型i的制备方法
CN108017619B (zh) * 2017-12-06 2020-08-11 成都惟邦药业有限公司 一种托匹司他杂质及其制备方法
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途
CN113666909B (zh) * 2020-05-14 2024-07-02 鲁南制药集团股份有限公司 一种托匹司他的制备方法
CN114773262B (zh) * 2022-05-19 2024-05-07 兄弟科技股份有限公司 2-氰基-4-吡啶羧酸甲酯的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7112373A (pt) * 1970-09-25 1972-03-28
US3947577A (en) * 1973-05-21 1976-03-30 Merck & Co., Inc. Anti-hyperuricemia composition
US3963731A (en) * 1973-05-21 1976-06-15 Merck & Co., Inc. Pyridyl containing 1-benzenesulfonyl triazoles
US3984558A (en) * 1973-05-21 1976-10-05 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds used as bronchodilators
US3928361A (en) * 1973-05-21 1975-12-23 Merck & Co Inc 1-(Sulfamoylphenylalkyl)-3,5-dipyridyl-1,2,4 triazoles
US3882134A (en) * 1973-05-21 1975-05-06 Merck & Co Inc 1-Substituted-3,5-dipyridyl-1,2,4-triazoles
US4104393A (en) * 1976-04-02 1978-08-01 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds
EP0626068B1 (en) * 1991-12-05 1999-05-06 Wallac Oy Luminescent lanthanide chelates
EP1123287B1 (en) * 1998-10-23 2003-07-30 Dow AgroSciences LLC Insecticidal 3- (substituted pyridyl) -1, 2, 4-triazoles
ATE375340T1 (de) * 2001-02-21 2007-10-15 Nps Pharma Inc Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten

Also Published As

Publication number Publication date
ES2300486T3 (es) 2008-06-16
TW200302222A (en) 2003-08-01
DE60225341T2 (de) 2009-04-09
PL208260B1 (pl) 2011-04-29
AR042602A1 (es) 2005-06-29
JP3600832B2 (ja) 2004-12-15
EP1471065A1 (en) 2004-10-27
PT1471065E (pt) 2008-03-13
RU2293733C2 (ru) 2007-02-20
AU2002349754B2 (en) 2008-01-31
NZ531673A (en) 2006-06-30
ZA200401777B (en) 2005-08-31
DE60225341D1 (de) 2008-04-10
US7074816B2 (en) 2006-07-11
BRPI0212775B1 (pt) 2017-06-06
NO326941B1 (no) 2009-03-16
RU2004106554A (ru) 2005-07-27
PL368672A1 (en) 2005-04-04
CN1561340A (zh) 2005-01-05
US20050004175A1 (en) 2005-01-06
WO2003064410A1 (fr) 2003-08-07
CA2462132A1 (en) 2003-08-07
HK1067132A1 (pt) 2005-04-01
DK1471065T3 (da) 2008-03-25
NO20041075L (no) 2004-03-15
CN1561340B (zh) 2012-05-23
ATE387438T1 (de) 2008-03-15
BRPI0212775B8 (pt) 2021-05-25
JPWO2003064410A1 (ja) 2005-05-26
CA2462132C (en) 2010-08-10
TWI257926B (en) 2006-07-11
EP1471065B1 (en) 2008-02-27
EP1471065A4 (en) 2005-06-15
MXPA04004037A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
BR0212775A (pt) Composto de 1,2,4-triazol
TW200510381A (en) Novel 2-pyridinecarboxamide derivatives
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
BR0206943A (pt) Inibidores de fosfodiesterase 4
WO2004103977A3 (en) Process for the preparation of pyrimidine derivatives
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
WO2004012663A3 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
BR0211652A (pt) Processo para produção de composto de piridina
DE60015390D1 (de) Antidiabetische thiazolidindione und ihre herstellung
EP1794120A4 (en) peptidase
HUP0003942A2 (hu) Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
DE60316436D1 (de) Amidderivate als inhibitoren der enzymatischen aktivität von renin
MA27143A1 (fr) Utilisation de derives de 2-amino-4- pyridylmethyl-thiazoline comme inhibiteurs de no-synthase inductible
DE60230781D1 (en) Reverse hydroxamsäurederivate
NZ236026A (en) 6-phenyl-, pyridyl-, furanyl- and thienyl- substituted 5,6-dihydroimidazo (2,1-b) thiazole derivatives; preparatory processes, intermediates therefor and pharmaceutical compositions
GB0215392D0 (en) Chemical compounds
MXPA04000046A (es) Proceso para la preparacion de las formas enantiomericas de los derivados de acido 2-(2,5-dioxoimidazolidin-1-il)-acetico 2-sustituidos.
CO5660293A2 (es) Fluorbutenos nematicidad que contienen tiazolina
TW200602331A (en) Process for preparing thiazole compound
WO2003049541A3 (en) Nematicidal trifluorobutenyl imidazole thioether derivatives
NO20023513L (no) Anvendelse av et ekstraheringsmiddel som et antiskummiddel ved fremstilling av vannfri maursyre
BR0312615A (pt) Compostos úteis como inibidores de metaloproteinases
TW200519071A (en) 3-aryl-2-cyano-3-hydroxy-acrylic acid derivatives
BR9810687A (pt) Processo para a preparação de um composto derivado de 2-alquiltiobenzonitrila, e, composto derivado de 2-alquiltiobenzonitrila

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2699 DE 27-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.